MEK inhibitors vs chemotherapy alone
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 2.01 [1.35, 2.99]496 participantsHigh
Findings
What do systematic reviews say?
4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only
No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
MEK inhibitors vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.61 [1.08, 2.41]91 participantsModerate
BRAF plus MEK inhibitors vs BRAF inhibitors
Overall survival† · people with cutaneous melanoma
BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).
1 finding from 1 review
- HR 0.7 [0.59, 0.82]1784 participantsHigh
BRAF plus MEK inhibitors vs BRAF inhibitors
Progression‐free survival · people with cutaneous melanoma
BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).
1 finding from 1 review
- HR 0.56 [0.44, 0.71]1784 participantsModerate
BRAF plus MEK inhibitors vs BRAF inhibitors
Tumour response · people with cutaneous melanoma
BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).
1 finding from 1 review
- RR 1.32 [1.2, 1.46]1784 participantsHigh
BRAF plus MEK inhibitors vs BRAF inhibitors
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).
1 finding from 1 review
- RR 1.01 [0.85, 1.2]1774 participantsModerate
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.6 [0.45, 0.81]324 participantsModerate
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 3.42 [2.38, 4.92]1367 participantsHigh
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.69 [0.52, 0.92]324 participantsModerate
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.71 [0.96, 3.03]324 participantsModerate
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
- RR 0.68 [0.09, 5.32]324 participantsLow
Biochemotherapy vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.94 [0.84, 1.06]1317 participantsHigh
Biochemotherapy vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.9 [0.83, 0.99]964 participantsHigh
Biochemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 1.36 [1.12, 1.66]770 participantsHigh
Biochemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 1.35 [1.14, 1.61]631 participantsHigh
Polychemotherapy vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.99 [0.85, 1.16]594 participantsHigh
Polychemotherapy vs chemotherapy alone
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 1.07 [0.91, 1.25]398 participantsHigh
Polychemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.27 [1.02, 1.58]1885 participantsModerate
Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
- 0.55 [0.31, 0.97]1360 participantsLow
Polychemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.97 [1.44, 2.71]390 participantsModerate